{"id":"aspartic-acid","rwe":[{"pmid":"41903465","year":"2026","title":"Metabolite-based genome-wide association analysis reveals genetic loci and candidate genes affecting breast muscle metabolites in Sansui ducks.","finding":"","journal":"Poultry science","studyType":"Clinical Study"},{"pmid":"41901708","year":"2026","title":"Genotypic and Phenotypic Characterisation of Staphylococcus aureus Enterotoxins Using Single-Cell Raman Spectroscopy and Metabolomics.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41898315","year":"2026","title":"EEG Time-Frequency Clustering Reveals Spectral Signatures of Glutamatergic and Cholinergic Activities and Their Interrelations.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"},{"pmid":"41898192","year":"2026","title":"Serum Amino Acid and Fatty Acid Metabolites as Predictors of Sleep Disorders in Children: A Risk Prediction Model.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"},{"pmid":"41897948","year":"2026","title":"Impact of Dietary Lactobacillus plantarum on Muscle Composition, Hemolymph Biochemistry, Lipid Metabolism, and the mTOR Signaling Pathway in Red Claw Crayfish (Cherax quadricarinatus).","finding":"","journal":"Animals : an open access journal from MDPI","studyType":"Clinical Study"}],"_fda":{"id":"488d78ac-3cd2-4593-8968-2992fe59bb49","set_id":"2d212e10-7e08-4aeb-b63f-dcc927897769","openfda":{"nui":["N0000175780","M0000922"],"unii":["OF5P57N2ZX","94ZLA3W45F","30KYC7MIAI","3KX376GY7L","TE7660XO1C","4QD397987E","04Y7590D77","GMW67QNF9C","TTL6G7LIWZ","AE28F7PNPL","47E5O17Y3R","9DLQ4CIU6V","452VLY9402","1EQV5MLY3D","2ZD004190S","8DUH1N11BX","42HK56048U","HG18B9YRS7"],"route":["INTRAVENOUS"],"rxcui":["831426","831430"],"spl_id":["488d78ac-3cd2-4593-8968-2992fe59bb49"],"brand_name":["Aminosyn-PF"],"spl_set_id":["2d212e10-7e08-4aeb-b63f-dcc927897769"],"package_ndc":["0990-4178-03"],"product_ndc":["0990-4178"],"generic_name":["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Amino Acids [CS]"],"substance_name":["ALANINE","ARGININE","ASPARTIC ACID","GLUTAMIC ACID","GLYCINE","HISTIDINE","ISOLEUCINE","LEUCINE","LYSINE ACETATE","METHIONINE","PHENYLALANINE","PROLINE","SERINE","TAURINE","THREONINE","TRYPTOPHAN","TYROSINE","VALINE"],"pharm_class_epc":["Amino Acid [EPC]"],"manufacturer_name":["ICU Medical Inc."],"application_number":["NDA019398"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Safe, effective use of parenteral nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. FREQUENT EVALUATION AND LABORATORY DETERMINATIONS ARE NECESSARY FOR PROPER MONITORING OF PARENTERAL NUTRITION. Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide content, serum osmolalities, blood cultures, and blood ammonia levels. Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. Patients with azotemia from any cause should not be infused with amino acids without regard to total nitrogen intake. Administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the solutions. Administration of amino acid solutions to a patient with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Hyperammonemia is of special significance in infants , as its occurrence in the syndrome caused by genetic metabolic defects is sometimes associated, although not necessarily in a causal relationship, with mental retardation. This reaction appears to be dose-related and is more likely to develop during prolonged therapy. It is essential that blood ammonia be measured frequently in infants. Conservative doses of amino acids should be given, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid dosage levels should be reduced and titrated against serum ammonia levels. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS ."],"description":["DESCRIPTION Aminosyn ® -PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn ® -PF 7% is oxygen sensitive. The formulation is described below: Aminosyn-PF 7% An Amino Acid Injection — Pediatric Formula Essential Amino Acids (mg/100 mL) Isoleucine 534 Leucine 831 Lysine (acetate)* 475 Methionine 125 Phenylalanine 300 Threonine 360 Tryptophan 125 Valine 452 * Amount cited is for lysine alone and does not include the acetate salt. Nonessential Amino Acids (mg/100 mL) Alanine 490 Arginine 861 L-Aspartic Acid 370 L-Glutamic Acid 576 Glycine 270 Histidine 220 Proline 570 Serine 347 Taurine 50 Tyrosine 44 Electrolytes (mEq/L) Sodium (Na + ) (mEq/L) None Potassium (K + ) (mEq/L) None Chloride (Clˉ) (mEq/L) None Acetate (C 2 H 3 O 2 ˉ) a (mEq/L) 32.5 a From lysine acetate. Product Characteristics Protein Equivalent (Approx. grams/L) 70 Total Nitrogen (grams/L) 10.69 Osmolarity (mOsmol/L) 561 pH (range) 5.5 (5.0 to 6.5) The formulas for the individual amino acids present in Aminosyn-PF 7% are as follows: Essential Amino Acids Isoleucine, USP C 6 H 13 NO 2 Leucine, USP C 6 H 13 NO 2 Lysine Acetate, USP C 6 H 14 N 2 O 2 • CH 3 COOH Methionine, USP C 5 H 11 NO 2 S Phenylalanine, USP C 9 H 11 NO 2 Threonine, USP C 4 H 9 NO 3 Tryptophan, USP C 11 H 12 N 2 O 2 Valine, USP C 5 H 11 NO 2 Nonessential Amino Acids Alanine, USP C 3 H 7 NO 2 Glycine, USP C 2 H 5 NO 2 Arginine, USP C 6 H 14 N 4 O 2 L-Aspartic Acid C 4 H 7 NO 4 HO 2 CCH 2 CH(NH 2 )CO 2 H L-Glutamic Acid C 5 H 9 NO 4 HO 2 CCH 2 CHCH(NH 2 )CO 2 H Histidine, USP C 6 H 9 N 3 O 2 Proline, USP C 5 H 9 NO 2 Serine, USP C 3 H 7 NO 3 Taurine C 2 H 7 NO 3 S Tyrosine, USP C 9 H 11 NO 3 The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period."],"precautions":["PRECAUTIONS Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements. Strongly hypertonic nutrient solutions should be administered via an intravenous catheter placed in a central vein, preferably the superior vena cava. Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency. Special care must be taken when giving hypertonic dextrose to a diabetic or pre-diabetic patient. To prevent severe hyperglycemia in such patients, insulin may be required. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. The effect of infusion of amino acids, without dextrose, upon carbohydrate metabolism of children is not known at this time. It is essential to provide adequate exogenous dextrose calories concurrently with amino acids. Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrate. Essential fatty acid deficiency (EFAD) is becoming increasingly recognized in patients on long term TPN (more than 5 days). The use of fat emulsion to provide 4 — 10% of total caloric intake as linoleic acid may prevent EFAD. Peripheral administration of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) requires appropriate dilution and provision of adequate calories. Care should be taken to assure proper placement of the needle within the lumen of the vein. The venipuncture site should be inspected frequently for signs of infiltration. If venous thrombosis or phlebitis occurs, discontinue infusions or change infusion site and initiate appropriate treatment. Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea, or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Metabolic acidosis can be prevented or readily controlled by adding a portion of the cations in the electrolyte mixture as acetate salts and in the case of hyperchloremic acidosis, by keeping the total chloride content of the infusate to a minimum. Aminosyn-PF 7% contains no chloride. Aminosyn-PF 7% contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. To assure adequate intake, serum levels should be monitored frequently. Aminosyn-PF 7% contains no more than 25 mcg/L of aluminum. To minimize the risk of possible incompatabilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration. SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS. Central vein infusion (with added concentrated carbohydrate solutions) of amino acid solutions requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of complications. Attention must be given to solution preparation, administration and patient monitoring. IT IS ESSENTIAL THAT A CAREFULLY PREPARED PROTOCOL, BASED ON CURRENT MEDICAL PRACTICES, BE FOLLOWED, PREFERABLY BY AN EXPERIENCED TEAM. SUMMARY HIGHLIGHTS OF COMPLICATIONS (See also Current Medical Literature). 1. Technical The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion. For details of technique and placement sites, consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arteriovenous fistula, phlebitis, thrombosis and air and catheter emboli. 2. Septic The constant risk of sepsis is present during administration of total parenteral nutrition. It is imperative that the preparation of the solution and the placement and care of catheters be accomplished under strict aseptic conditions. Solutions should ideally be prepared in the hospital pharmacy under a laminar flow hood using careful aseptic technique to avoid inadvertent touch contamination. Solutions should be used promptly after mixing. Storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours. Administration time for a single container and set should never exceed 24 hours. 3. Metabolic The following metabolic complications have been reported with TPN administration: Metabolic acidosis and alkalosis, hypophosphatemia, hypocalcemia, osteoporosis, hyperglycemia and glycosuria, rebound hypoglycemia, osmotic diuresis and dehydration, elevated liver enzymes, hypo- and hypervitaminosis, electrolyte imbalances and hyperammonemia in children. Frequent evaluations are necessary especially during the first few days of therapy to prevent or minimize these complications. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma and death. CLINICAL EVALUATION AND LABORATORY DETERMINATIONS, AT THE DISCRETION OF THE ATTENDING PHYSICIAN ARE NECESSARY FOR PROPER MONITORING DURING ADMINISTRATION. Do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen-containing substances may occur. Blood studies should include glucose, urea nitrogen, serum electrolytes, ammonia, cholesterol, acid-base balance, serum proteins, kidney and liver function tests, osmolarity and hemogram. White blood count and blood cultures are to be determined if indicated. Urinary osmolality and glucose should be determined as necessary. Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"how_supplied":["HOW SUPPLIED NDC No. Concentration Container (mL) 0409-4178-03 Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection - 500 0990-4178-03 pediatric formula) ICU Medical is transitioning NDC codes from the \"0409\" to a \"0990\" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.] Protect from freezing. Avoid exposure to light. Revised: August, 2018 EN-4682 ICU Medical, Inc., Lake Forest, Illinois, 60045 USA"],"effective_time":"20251017","adverse_reactions":["ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary."],"contraindications":["CONTRAINDICATIONS Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism (including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia), or hypersensitivity to one or more amino acids present in the solution."],"description_table":["
Aminosyn-PF 7%An Amino Acid Injection — Pediatric Formula
Essential Amino Acids (mg/100 mL)
Isoleucine534
Leucine831
Lysine (acetate)*475
Methionine125
Phenylalanine300
Threonine360
Tryptophan125
Valine452
","
Nonessential Amino Acids (mg/100 mL)
Alanine490
Arginine861
L-Aspartic Acid370
L-Glutamic Acid576
Glycine270
Histidine220
Proline570
Serine347
Taurine50
Tyrosine44
","
Electrolytes (mEq/L)
Sodium (Na+) (mEq/L)None
Potassium (K+) (mEq/L)None
Chloride (Clˉ) (mEq/L)None
Acetate (C2H3O2ˉ)a (mEq/L)32.5
","
Product Characteristics
Protein Equivalent (Approx. grams/L)70
Total Nitrogen (grams/L)10.69
Osmolarity (mOsmol/L)561
pH (range)5.5 (5.0 to 6.5)
","
Essential Amino Acids
Isoleucine, USPC6H13NO2
Leucine, USPC6H13NO2
Lysine Acetate, USPC6H14N2O2 • CH3COOH
Methionine, USPC5H11NO2S
Phenylalanine, USPC9H11NO2
Threonine, USPC4H9NO3
Tryptophan, USPC11H12N2O2
Valine, USPC5H11NO2
","
Nonessential Amino Acids
Alanine, USPC3H7NO2
Glycine, USPC2H5NO2
Arginine, USPC6H14N4O2
L-Aspartic AcidC4H7NO4
HO2CCH2CH(NH2)CO2H
L-Glutamic AcidC5H9NO4
HO2CCH2CHCH(NH2)CO2H
Histidine, USPC6H9N3O2
Proline, USPC5H9NO2
Serine, USPC3H7NO3
TaurineC2H7NO3S
Tyrosine, USPC9H11NO3
"],"precautions_table":["
SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS
ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS.
"],"how_supplied_table":["
NDC No.ConcentrationContainer (mL)
0409-4178-03Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection -500
0990-4178-03pediatric formula)
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Aminosyn-PF 7% Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 7% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 7% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 7% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 7% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 7% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development."],"indications_and_usage":["INDICATIONS AND USAGE Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. See DOSAGE AND ADMINISTRATION for additional information. Central Venous Infusion Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5 to 10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion."],"spl_unclassified_section":["AN AMINO ACID INJECTION - PEDIATRIC FORMULA Flexible Plastic Container Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response. Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult. The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is up to 2.5 g amino acid/kg/day for infants up to 10 kg. For infants and children larger than 10 kg, the total daily dose of amino acids should be up to 25 g amino acids/day for the first 10 kg of body weight plus 1 to 1.25 g amino acid for each kg of body weight over 10 kg. Initial amino acid dosage levels of 1 g/kg/day may be increased gradually in increments of 0.5 g/kg/day to approximate desired intake levels. Aminosyn-PF 7% should be diluted with dextrose prior to use. Nonprotein calories should constitute approximately 100 to 130 kcal/kg/day. Part of the nonprotein caloric requirement may be provided as lipid emulsion administered concurrently to provide up to 60% of daily calories at a dose not to exceed 4 g fat/kg/day. Fluid intake for the infant receiving central venous TPN should be approximately 125 mL/kg/day (range: 100 to 175 mL/kg/day), depending on the clinical condition of the patient. Premature infants with respiratory distress syndrome suspected of having a patent ductus arteriosus should be given fluids more cautiously. Cysteine is considered to be an essential amino acid for infants, especially preterm infants with potentially immature enzyme pathways. Therefore, addition of a cysteine supplement to the TPN admixture is recommended. The intake of cysteine by the preterm infant ingesting maternal milk is approximately 78 mg/kg/day. The suggested intravenous dosage level for Cysteine Hydrochloride Injection, USP is 500 mg (10 mL) for every 12.5 g (179 mL) of Aminosyn-PF 7% administered (see package insert for Cysteine Hydrochloride Injection, USP). In order to avoid potential insolubility of cysteine hydrochloride in admixtures, the foregoing concentration should not be exceeded. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose solutions are abruptly discontinued. SERUM ELECTROLYTES SHOULD BE MONITORED FREQUENTLY. Electrolytes may be added to the nutrient solution as indicated by the patient's clinical condition and laboratory determinations of plasma values. Major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. Daily administration of intravenous vitamin supplements including a complete complement of fat and water-soluble vitamins is required. Trace metal additives including zinc, copper, manganese, and chromium should also be provided, especially when long-term parenteral therapy is anticipated. Calcium and phosphorus are added to the solution as indicated. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate bottles to avoid precipitation. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. Bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. To ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in infants, accurately calibrated and reliable infusion systems should be used. Central Venous Nutrition Hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the superior vena cava. Initial infusion rates should be slow, and gradually increased to the recommended 60-125 mL per kilogram body weight per day. If administration rate should fall behind schedule, no attempt to \"catch up\" to planned intake should be made. In addition to meeting protein needs, the rate of administration, particularly during the first few days of therapy, is governed by the patient's glucose tolerance. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of glucose levels in blood and urine. Peripheral Parenteral Nutrition For patients in whom the central venous route is not indicated and who can consume adequate calories enterally, Aminosyn-PF 7% may be administered by peripheral vein with parenteral nonprotein calories. The concentration of dextrose in the final admixture is 5 to 10%, and simultaneous administration of lipid emulsion is recommended both as a calorie source and to attenuate the potentially irritating effects of the hypertonic nutritional admixture. Fat emulsion may comprise up to 60% of the daily caloric intake at a dosage level not to exceed 4 g fat/kg/day. It is essential that peripheral infusion be accompanied by adequate caloric intake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. WARNING: Do not use flexible container in series connections."],"spl_product_data_elements":["Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE ISOLEUCINE ISOLEUCINE LEUCINE LEUCINE LYSINE ACETATE LYSINE METHIONINE METHIONINE PHENYLALANINE PHENYLALANINE THREONINE THREONINE TRYPTOPHAN TRYPTOPHAN VALINE VALINE ALANINE ALANINE ARGININE ARGININE ASPARTIC ACID ASPARTIC ACID GLUTAMIC ACID GLUTAMIC ACID GLYCINE GLYCINE HISTIDINE HISTIDINE PROLINE PROLINE SERINE SERINE TAURINE TAURINE TYROSINE TYROSINE WATER"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 500 mL Bag Label 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION – PEDIATRIC FORMULA EACH 100 mL CONTAINS: TOTAL AMINO ACIDS APPROX. 7 g. ESSENTIAL AMINO ACIDS/100 mL : ISOLEUCINE 534 mg; LEUCINE 831 mg; LYSINE (AS ACETATE SALT) 475 mg; METHIONINE 125 mg; PHENYLALANINE 300 mg; THREONINE 360 mg; TRYPTOPHAN 125 mg; VALINE 452 mg. NONESSENTIAL AMINO ACIDS/100 mL: TYROSINE 44 mg; ALANINE 490 mg; ARGININE 861 mg; GLYCINE 270 mg; PROLINE 570 mg; HISTIDINE 220 mg; SERINE 347 mg; L-GLUTAMIC ACID 576 mg; L-ASPARTIC ACID 370 mg; TAURINE 50 mg. ELECTROLYTES (mEq/LITER): ACETATE 32.5. pH 5.5 (5.0 to 6.5) 561 mOsmol/LITER SPECIFIC GRAVITY = 1.02 ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE DOSE CONTAINER. CONTAINS NO BACTERIOSTAT. DISCARD UNUSED PORTION. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. STORE AT 20 TO 25°C (68 TO 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.] AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. AVOID EXPOSURE TO LIGHT. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. RX ONLY IM-4405 3 v CONTAINS DEHP icumedical ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label","PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label TO OPEN – TEAR AT NOTCH 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION — PEDIATRIC FORMULA Each 100 mL contains: Total amino acids approx. 7 g. Essential Amino Acids/100 mL: Isoleucine 534 mg; leucine 831 mg; lysine (as acetate salt) 475 mg; methionine 125 mg; phenylalanine 300 mg; threonine 360 mg; tryptophan 125 mg; valine 452 mg. Nonessential Amino Acids/100 mL: Tyrosine 44 mg; alanine 490 mg; arginine 861 mg; glycine 270 mg; proline 570 mg; histidine 220 mg; serine 347 mg; L-glutamic acid 576 mg; L-aspartic acid 370 mg; taurine 50 mg. Electrolytes (mEq/Liter): Acetate 32.5. 561 mOsmol/Liter pH 5.5 (5.0 to 6.5) Specific Gravity = 1.02 Single dose container. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. Rx only 7 OTHER icumedical F WR-0544 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label"]},"tags":[{"label":"aspartic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Excitatory amino acid transporter 1","category":"target"},{"label":"SLC1A3","category":"gene"},{"label":"SLC1A1","category":"gene"},{"label":"SLC1A2","category":"gene"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"Hypokalemia","category":"indication"},{"label":"Hypokalemia Prevention","category":"indication"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"CHILLS","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"CHEST DISCOMFORT","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"PALPITATIONS","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"19 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pyrexia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypertension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hemoglobin decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Protein total decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypokalemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood potassium decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Gamma-glutamyltransferase increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hyperglycemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood alkaline phosphatase increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood calcium decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Prothrombin time prolonged","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pruritus","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cholestasis","drugRate":"reported","severity":"unknown"},{"effect":"Infection","drugRate":"reported","severity":"unknown"},{"effect":"Subependymal hemorrhage","drugRate":"reported","severity":"serious"}],"contraindications":["Acute nephropathy","Chronic diarrhea","Complete atrioventricular block","Congenital myotonia, autosomal dominant form","Diarrhea","Familial hyperkalemic periodic paralysis","Gastrointestinal obstruction","Gastrointestinal ulcer","Gastroparesis","Hyperkalemia","Hyporeninemic hypoaldosteronism","Kidney disease","Severe dehydration"],"specialPopulations":{"Pregnancy":"PERIKABIVEN (R) should be given to pregnant woman only if clearly needed. Severe malnutrition in pregnant woman is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if pregnant womans nutritional requirements cannot be fulfilled by oral or enteral intake.","Geriatric use":"Clinical Studies of Aminosyn II have not been performed to determine whether patients over 65 years of age respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.","Paediatric use":"Safety and effectiveness of solutions from flexible plastic containers in pediatric patients have not been well established. Clinical Studies of Aminosyn II have not been performed to determine whether patients over 65 years of age respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. If required, adjust the volume of PERIKABIVEN (R) administered based on serum electrolyte levels and fluid balance.","Renal impairment":"Patients on dialysis or continuous renal replacement therapy may require additional protein supplementation to meet nutritional requirements. If required, adjust the volume of PERIKABIVEN (R) administered based on serum electrolyte levels and fluid balance."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ASPARTIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:55.670240+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:39:01.283699+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:38:54.773505+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ASPARTIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:39:01.599288+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:49.671638+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:49.671666+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:49.671671+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:39:03.575931+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL274323/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:39:02.765939+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019398","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:49.671674+00:00"}},"allNames":"asparagic acid","offLabel":[],"synonyms":["L-Aspartic acid","asparagic acid","aspartic acid"],"timeline":[],"brandName":"Asparagic Acid","ecosystem":[{"indication":"Hypokalemia","otherDrugs":[{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"potassium acetate","slug":"potassium-acetate","company":"B Braun"},{"name":"potassium chloride","slug":"potassium-chloride","company":"Hospira"},{"name":"potassium citrate","slug":"potassium-citrate","company":"Mission Pharma"}],"globalPrevalence":null},{"indication":"Hypokalemia Prevention","otherDrugs":[{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"potassium acetate","slug":"potassium-acetate","company":"B Braun"},{"name":"potassium chloride","slug":"potassium-chloride","company":"Hospira"}],"globalPrevalence":null}],"mechanism":{"target":"Excitatory amino acid transporter 1","targets":[{"gene":"SLC1A3","source":"DrugCentral","target":"Excitatory amino acid transporter 1","protein":"Excitatory amino acid transporter 1"},{"gene":"SLC1A1","source":"DrugCentral","target":"Excitatory amino acid transporter 3","protein":"Excitatory amino acid transporter 3"},{"gene":"SLC1A2","source":"DrugCentral","target":"Excitatory amino acid transporter 2","protein":"Excitatory amino acid transporter 2"},{"gene":"ACY1","source":"DrugCentral","target":"Aminoacylase-1","protein":"Aminoacylase-1"},{"gene":"ASS1","source":"DrugCentral","target":"Argininosuccinate synthase","protein":"Argininosuccinate synthase"},{"gene":"ASNS","source":"DrugCentral","target":"Asparagine synthetase [glutamine-hydrolyzing]","protein":"Asparagine synthetase [glutamine-hydrolyzing]"},{"gene":"GOT1","source":"DrugCentral","target":"Aspartate aminotransferase, cytoplasmic","protein":"Aspartate aminotransferase, cytoplasmic"},{"gene":"GOT2","source":"DrugCentral","target":"Aspartate aminotransferase, mitochondrial","protein":"Aspartate aminotransferase, mitochondrial"},{"gene":"DARS","source":"DrugCentral","target":"Aspartate--tRNA ligase, cytoplasmic","protein":"Aspartate--tRNA ligase, cytoplasmic"},{"gene":"ASPA","source":"DrugCentral","target":"Aspartoacylase","protein":"Aspartoacylase"}],"modality":"Small Molecule","drugClass":"Amino Acid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Aspartic acid acts as a competitive inhibitor of the excitatory amino acid transporter 1 (EAAT1), a sodium-dependent transporter that regulates the uptake of glutamate and aspartate in the brain and other tissues."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1550","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ASPARTIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ASPARTIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:46:19.045298","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:39:05.703847+00:00","fieldsConflicting":16,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"aspartic acid","indications":{"approved":[{"name":"Hypokalemia","source":"DrugCentral","snomedId":43339004,"regulator":"FDA","eligibility":"Infants (including those of low birth weight) and young pediatric patients"},{"name":"Hypokalemia Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Infants and young pediatric patients where the alimentary tract cannot or should not be used, or adequate protein intake is not feasible, or gastrointestinal absorption of protein is impaired, or protein requirements are substantially increased as with extensive burns"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07149649","phase":"PHASE2,PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer"],"enrollment":230,"completionDate":"2035-03-31"},{"nctId":"NCT06867068","phase":"PHASE1","title":"Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-10-04","conditions":["Anesthesia","Tooth Extraction"],"enrollment":73,"completionDate":"2024-06-10"},{"nctId":"NCT02543983","phase":"PHASE2","title":"Neurobiology of Suicide","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2015-12-01","conditions":["Healthy Volunteers","Depression"],"enrollment":325,"completionDate":"2030-07-21"},{"nctId":"NCT06547489","phase":"PHASE2","title":"Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2025-02-03","conditions":["Major Depressive Disorder"],"enrollment":164,"completionDate":"2027-12"},{"nctId":"NCT07099989","phase":"PHASE1","title":"Pharmacokinetics of Zelquistinel in Fasted or Fed State","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2025-07-24","conditions":["Healthy Volunteers in Fed and Fasted State"],"enrollment":32,"completionDate":"2026-07"},{"nctId":"NCT07115329","phase":"PHASE2","title":"A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2026-01-05","conditions":["Major Depressive Disorder"],"enrollment":164,"completionDate":"2028-06"},{"nctId":"NCT05042245","phase":"PHASE4","title":"The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-07-23","conditions":["Non-alcoholic Fatty Liver Disease"],"enrollment":237,"completionDate":"2022-12-20"},{"nctId":"NCT04953910","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2022-12-23","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":27,"completionDate":"2026-12"},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":["NMDAR Autoimmune Encephalitis","LGI1 Autoimmune Encephalitis"],"enrollment":152,"completionDate":"2029-12-14"},{"nctId":"NCT07442552","phase":"","title":"Perioperative Sepsis. An Epigenetic Perspective","status":"RECRUITING","sponsor":"Carol Davila University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":["Sepsis Abdominal"],"enrollment":40,"completionDate":"2026-04-10"},{"nctId":"NCT06575153","phase":"PHASE1","title":"Phase 1 Study of ART5803 in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arialys Therapeutics","startDate":"2024-09-19","conditions":["Autoimmune Encephalitis"],"enrollment":64,"completionDate":"2026-03-11"},{"nctId":"NCT07377786","phase":"","title":"Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-02-01","conditions":["HELLP Syndrome"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT07377032","phase":"PHASE3","title":"TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-08-29","conditions":["GRIN-related Disorders","GRIN1","GRIN2A","GRIN2B","GRIN2D","Epilepsy","Neurodevelopmental Disorder (Diagnosis)"],"enrollment":40,"completionDate":"2028-06"},{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":["Heart Failure With Preserved Ejection Fraction","Obesity, Mild","Decompensated Heart Failure"],"enrollment":240,"completionDate":"2026-07-31"},{"nctId":"NCT07360405","phase":"NA","title":"Dietary Intervention for Migraine Relief","status":"NOT_YET_RECRUITING","sponsor":"American University","startDate":"2026-01","conditions":["Migraine"],"enrollment":40,"completionDate":"2027-03"},{"nctId":"NCT03065335","phase":"PHASE1","title":"Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2017-05-25","conditions":["Healthy Volunteer","Major Depressive Disorder","Depression"],"enrollment":150,"completionDate":"2028-01-01"},{"nctId":"NCT05569759","phase":"PHASE2","title":"A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2023-05-23","conditions":["Autoimmune Hepatitis"],"enrollment":24,"completionDate":"2025-04-30"},{"nctId":"NCT07334223","phase":"NA","title":"Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering","status":"COMPLETED","sponsor":"Mayo Hospital Lahore","startDate":"2020-01-01","conditions":["Postoperative Shivering","Postspinal Shivering"],"enrollment":180,"completionDate":"2020-06-30"},{"nctId":"NCT07310524","phase":"NA","title":"COMPARISON OF OPIOID-FREE AND OPIOID-BASED ANESTHESIA TECHNIQUES ON qNOX INDEX IN ABDOMINAL SURGERY UNDER GENERAL ANESTHESIA","status":"COMPLETED","sponsor":"Muhammad Rahman Efendi Nasution","startDate":"2025-09-08","conditions":["Opioid-free Anesthesia"],"enrollment":42,"completionDate":"2025-12-01"},{"nctId":"NCT03736538","phase":"PHASE1","title":"Nitrous Oxide- Suicidal Ideation","status":"ENROLLING_BY_INVITATION","sponsor":"Washington University School of Medicine","startDate":"2018-10-30","conditions":["Major Depressive Disorder","Depression","Mood Disorders","Suicidal Ideation"],"enrollment":50,"completionDate":"2026-12"},{"nctId":"NCT06309277","phase":"PHASE2","title":"A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD","status":"COMPLETED","sponsor":"Gilgamesh Pharmaceuticals","startDate":"2024-02-01","conditions":["Major Depressive Disorder"],"enrollment":46,"completionDate":"2025-03-27"},{"nctId":"NCT07117630","phase":"PHASE2","title":"An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-25","conditions":["Breast Cancer"],"enrollment":20,"completionDate":"2027-08"},{"nctId":"NCT05967741","phase":"NA","title":"The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-07-20","conditions":["Platelet Aggregation, Spontaneous","Vascular Thrombosis"],"enrollment":24,"completionDate":"2026-06"},{"nctId":"NCT04398680","phase":"PHASE1","title":"A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2021-04-20","conditions":["Multiple Myeloma"],"enrollment":0,"completionDate":"2025-11-04"},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":["Acute Myeloid Leukemia","Leukemia Cutis","Myeloid Neoplasm","Myeloid Sarcoma"],"enrollment":1645,"completionDate":"2027-09-30"},{"nctId":"NCT06944275","phase":"","title":"Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-05-01","conditions":["Haemorrhagic Fever With Renal Syndrome"],"enrollment":62,"completionDate":"2027-08-31"},{"nctId":"NCT06592014","phase":"PHASE1,PHASE2","title":"Lithium for Parkinson's: an Extension Trial","status":"ENROLLING_BY_INVITATION","sponsor":"State University of New York at Buffalo","startDate":"2024-08-09","conditions":["Parkinson Disease"],"enrollment":35,"completionDate":"2026-11-01"},{"nctId":"NCT07211841","phase":"NA","title":"Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-12","conditions":["Glioblastoma","MRI Spectroscopy","Tumor Microenvironment","Biomarkers / Blood"],"enrollment":30,"completionDate":"2029-04"},{"nctId":"NCT04833907","phase":"PHASE1,PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":["Canavan Disease"],"enrollment":24,"completionDate":"2027-08-31"},{"nctId":"NCT06789757","phase":"PHASE2","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-02-25","conditions":["Hepatocellular Carcinoma"],"enrollment":19,"completionDate":"2028-01-27"},{"nctId":"NCT06284473","phase":"PHASE4","title":"Ketamine as a Supplement to Local Anesthesia for Minor Procedures","status":"RECRUITING","sponsor":"Loyola University","startDate":"2022-05-25","conditions":["Pain, Procedural","Minor Laceration","Abscess"],"enrollment":108,"completionDate":"2028-05-31"},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":["Protein Metabolism"],"enrollment":50,"completionDate":"2026-09"},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":["Chronic Obstructive Pulmonary Disease","Pulmonary Artery Hypertension","Heart Failure","Hypertension"],"enrollment":420,"completionDate":"2026-08"},{"nctId":"NCT06753955","phase":"PHASE1","title":"Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arialys Therapeutics","startDate":"2025-03-18","conditions":["Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody","Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)","Autoimmune Encephalitis"],"enrollment":6,"completionDate":"2025-12-24"},{"nctId":"NCT05619692","phase":"PHASE2","title":"A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2022-11-29","conditions":["Mild Cognitive Impairment","Mild Dementia","Alzheimer's Disease"],"enrollment":174,"completionDate":"2024-07-09"},{"nctId":"NCT07167251","phase":"","title":"Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-08-25","conditions":["Immune Related Adverse Events","Immune-Mediated Hepatitis","Cancer"],"enrollment":63,"completionDate":"2026-12-31"},{"nctId":"NCT06003400","phase":"NA","title":"Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the \"FITT\" Device in Diabetic Foot Ulcers Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tri.O Medical LTD","startDate":"2023-03-29","conditions":["Diabetic Foot Ulcer"],"enrollment":20,"completionDate":"2026-01"},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":["SLE","Lupus","Systemic Lupus Erthematosus","Systemic Lupus Erythematosus","Systemic Lupus Erythematosus (SLE)"],"enrollment":10,"completionDate":"2026-07"},{"nctId":"NCT05045378","phase":"PHASE4","title":"Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2022-03-15","conditions":["Treatment-resistant Depression","Major Depressive Disorder"],"enrollment":12,"completionDate":"2024-11-30"},{"nctId":"NCT07144501","phase":"NA","title":"Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09-15","conditions":["Congenital Heart Disease","Liver Dysfunction"],"enrollment":40,"completionDate":"2026-03-15"},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":["Overt Hepatic Encephalopathy"],"enrollment":174,"completionDate":"2027-06-30"},{"nctId":"NCT06099886","phase":"PHASE1","title":"Repurposing Lithium for Parkinson's Disease","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2023-10-12","conditions":["Parkinson's Disease"],"enrollment":17,"completionDate":"2025-04-30"},{"nctId":"NCT06810765","phase":"PHASE2","title":"Trifecta Research Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2025-09","conditions":["PTSD - Post Traumatic Stress Disorder","Cognitive Dysfunction","Brain Trauma","Brain Injuries"],"enrollment":0,"completionDate":"2027-12"},{"nctId":"NCT06387667","phase":"NA","title":"Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","status":"NOT_YET_RECRUITING","sponsor":"New Valley University","startDate":"2025-12-01","conditions":["Immunocompromised ICU Patients With Respiratory Tract Infections"],"enrollment":250,"completionDate":"2027-06-01"},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":["Acute Myeloid Leukemia","Down Syndrome","Myelodysplastic Syndrome","Myeloid Leukemia Associated With Down Syndrome","Myeloproliferative Neoplasm"],"enrollment":280,"completionDate":"2026-06-30"},{"nctId":"NCT07093333","phase":"PHASE2","title":"A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease","status":"NOT_YET_RECRUITING","sponsor":"Arialys Australia Pty Ltd","startDate":"2025-08-01","conditions":["Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)","Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease","Autoimmune Encephalitis"],"enrollment":30,"completionDate":"2027-03-30"},{"nctId":"NCT06620835","phase":"PHASE2","title":"Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib","status":"RECRUITING","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2025-06-19","conditions":["NSCLC"],"enrollment":45,"completionDate":"2030-10-01"},{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":["Anti-N-Methyl-D-Aspartate Receptor Encephalitis"],"enrollment":200,"completionDate":"2027-11-08"},{"nctId":"NCT03794362","phase":"","title":"Measuring Analgesic Interventions","status":"RECRUITING","sponsor":"Julia Finkel","startDate":"2018-10-29","conditions":["Pain"],"enrollment":120,"completionDate":"2025-12"},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":["Overt Hepatic Encephalopathy"],"enrollment":252,"completionDate":"2025-04-30"},{"nctId":"NCT04126005","phase":"","title":"Natural History Study of Patients With Canavan Disease (CANinform Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aspa Therapeutics","startDate":"2019-10-10","conditions":["Canavan Disease"],"enrollment":70,"completionDate":"2025-07-31"},{"nctId":"NCT07028606","phase":"PHASE1","title":"Vertical Ridge Augmentation Using Computer-guided Sandwich Osteotomy Technique","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-05-09","conditions":["Alveolar Bone Resorption"],"enrollment":12,"completionDate":"2025-06-10"},{"nctId":"NCT07023159","phase":"","title":"Predicting 28-Day Survival in OHCA Patients","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2023-05-01","conditions":["Out of Hospital Cardiac Arrest","Cardiac Arrest (CA)"],"enrollment":327,"completionDate":"2024-06-01"},{"nctId":"NCT01808352","phase":"","title":"HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2013-08-15","conditions":["HIV"],"enrollment":226,"completionDate":"2015-09-30"},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1895,"completionDate":"2025-03-31"},{"nctId":"NCT06936605","phase":"NA","title":"RGD With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2025-04-15","conditions":["Intrabony Defect","Periodontal Diseases","Alveolar Bone Loss"],"enrollment":45,"completionDate":"2025-10-20"},{"nctId":"NCT06910098","phase":"NA","title":"Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels","status":"COMPLETED","sponsor":"Central Park Medical College","startDate":"2023-12-01","conditions":["LDL - Low Density Lipoprotein Receptor Disorder","Rosuvastatin"],"enrollment":195,"completionDate":"2024-08-31"},{"nctId":"NCT05565352","phase":"","title":"Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Gdansk","startDate":"2022-09-01","conditions":["Major Depressive Disorder","Post Traumatic Stress Disorder","Obsessive-Compulsive Disorder","Somatoform Disorders","Anxiety Disorders","Dissociative Disorder"],"enrollment":140,"completionDate":"2029-12-31"},{"nctId":"NCT05786599","phase":"PHASE2,PHASE3","title":"Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-03-21","conditions":["Chemotherapy-induced Peripheral Neuropathy"],"enrollment":50,"completionDate":"2026-03"},{"nctId":"NCT04101474","phase":"NA","title":"Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-09-01","conditions":["Treatment Resistant Depression"],"enrollment":36,"completionDate":"2021-10-01"},{"nctId":"NCT04964310","phase":"","title":"Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-08-31","conditions":["Acetaminophen","Drug-Induced Liver Injury","Pharmacogenetics","China"],"enrollment":339,"completionDate":"2026-12-31"},{"nctId":"NCT06361329","phase":"PHASE3","title":"Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-04-03","conditions":["ETP-ALL"],"enrollment":81,"completionDate":"2027-03-31"},{"nctId":"NCT06818149","phase":"","title":"Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-01-30","conditions":["Lung Cancer","Myocarditis Due to Drug"],"enrollment":50,"completionDate":"2028-12-30"},{"nctId":"NCT05737030","phase":"PHASE4","title":"Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Graz","startDate":"2023-02-06","conditions":["Cirrhosis"],"enrollment":55,"completionDate":"2025-12"},{"nctId":"NCT05177146","phase":"NA","title":"Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-05-04","conditions":["Bipolar Disorder (BD)","Suicidality"],"enrollment":16,"completionDate":"2025-01-10"},{"nctId":"NCT05435638","phase":"PHASE1","title":"Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2022-07-17","conditions":["Punctate Palmoplantar Keratoderma Type 1","Pachyonychia Congenita"],"enrollment":14,"completionDate":"2024-09-05"},{"nctId":"NCT04932512","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-06-17","conditions":["Steatohepatitis, Nonalcoholic"],"enrollment":160,"completionDate":"2024-02-28"},{"nctId":"NCT05539027","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-09-20","conditions":["Hepatic Encephalopathy"],"enrollment":140,"completionDate":"2024-10-31"},{"nctId":"NCT06108297","phase":"PHASE1","title":"Lithium Long COVID Dose-finding Study","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2023-10-12","conditions":["Long COVID"],"enrollment":5,"completionDate":"2024-05-02"},{"nctId":"NCT04998396","phase":"PHASE1,PHASE2","title":"A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)","status":"RECRUITING","sponsor":"Aspa Therapeutics","startDate":"2021-09-08","conditions":["Canavan Disease"],"enrollment":26,"completionDate":"2030-10-08"},{"nctId":"NCT04513288","phase":"NA","title":"ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2022-05-20","conditions":["Sepsis","Septic Shock"],"enrollment":130,"completionDate":"2026-11-20"},{"nctId":"NCT05218356","phase":"PHASE2","title":"Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2022-01-20","conditions":["COVID-19"],"enrollment":130,"completionDate":"2025-07-20"},{"nctId":"NCT06506643","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","status":"RECRUITING","sponsor":"Vector Vitale LLC","startDate":"2024-05-15","conditions":["CLL","Solid Tumor, Adult"],"enrollment":36,"completionDate":"2026-10-31"},{"nctId":"NCT06585852","phase":"NA","title":"Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2023-08-01","conditions":["Implant Dentistry"],"enrollment":18,"completionDate":"2024-10-15"},{"nctId":"NCT04546360","phase":"","title":"Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)","status":"COMPLETED","sponsor":"Hepatopancreatobiliary Surgery Institute of Gansu Province","startDate":"2020-09-08","conditions":["Compensated Advanced Chronic Liver Disease","Variceal Hemorrhage"],"enrollment":381,"completionDate":"2022-12-31"},{"nctId":"NCT04209296","phase":"","title":"Chart Review of Patients Undergoing Ketamine Infusions","status":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","startDate":"2019-12-03","conditions":["Major Depressive Disorder","Bipolar Disorder","Obsessive-Compulsive Disorder","Post Traumatic Stress Disorder"],"enrollment":891,"completionDate":"2023-09-14"},{"nctId":"NCT06337994","phase":"PHASE3","title":"Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-01","conditions":["Treatment of Cognitive Deficits After Traumatic Brain Injury"],"enrollment":60,"completionDate":"2024-08-01"},{"nctId":"NCT03809442","phase":"PHASE4","title":"Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery.","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2019-06-25","conditions":["Postoperative Analgesia"],"enrollment":116,"completionDate":"2023-08-31"},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":["Acute Lymphoblastic Leukemia","Acute Undifferentiated Leukemia","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":218,"completionDate":"2024-06-30"},{"nctId":"NCT01856920","phase":"PHASE2","title":"QUILT-3.006 for Recurrent Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2013-03-26","conditions":["Medullary Thyroid Cancer (MTC)"],"enrollment":35,"completionDate":"2018-05-08"},{"nctId":"NCT06435130","phase":"NA","title":"The Impact of Chokeberry Bioproducts on Metabolic Parameters and Antioxidant Potential","status":"COMPLETED","sponsor":"Medical University of Bialystok","startDate":"2022-05-01","conditions":["Diet, Healthy","Diabetes Mellitus","Hypertension","Obesity","Hypercholesterolemia"],"enrollment":102,"completionDate":"2022-08-30"},{"nctId":"NCT06403553","phase":"","title":"FC Change From Day 1 to Day 3 Associated With SALD","status":"COMPLETED","sponsor":"Chinese Medical Association","startDate":"2023-01-01","conditions":["Liver Dysfunction"],"enrollment":96,"completionDate":"2024-03-31"},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":["B-cell Childhood Acute Lymphoblastic Leukemia","L1 Childhood Acute Lymphoblastic Leukemia","L2 Childhood Acute Lymphoblastic Leukemia","Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia"],"enrollment":275,"completionDate":""},{"nctId":"NCT06306040","phase":"PHASE3","title":"Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-04-02","conditions":["Emergence Delirium"],"enrollment":105,"completionDate":"2025-01-30"},{"nctId":"NCT06299800","phase":"","title":"Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer","status":"RECRUITING","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2024-02-04","conditions":["Diabetes Mellitus, Type 2","Cancer"],"enrollment":779,"completionDate":"2025-02-04"},{"nctId":"NCT06296004","phase":"","title":"Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-03-01","conditions":["Behçet's Disease"],"enrollment":80,"completionDate":"2025-04-01"},{"nctId":"NCT06287125","phase":"","title":"Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-03-01","conditions":["Systemic Sclerosis and Systemic Lupus Erythematous"],"enrollment":95,"completionDate":"2027-03-01"},{"nctId":"NCT06125730","phase":"NA","title":"A Single-Group Study to Evaluate the Effects of an Eyelash Serum on Improving Eyelash Growth","status":"COMPLETED","sponsor":"Dime Beauty Co.","startDate":"2023-08-23","conditions":["Eyelash Growth"],"enrollment":35,"completionDate":"2024-02-10"},{"nctId":"NCT03941288","phase":"PHASE2","title":"Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-09-04","conditions":["Gastroparesis","Dyspepsia"],"enrollment":92,"completionDate":"2023-02-23"},{"nctId":"NCT06240468","phase":"","title":"Dynamic Changes in Human Microbiome Predict the Risk of Adverse Outcomes in Patients With Acute Ischemic Stroke: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2022-02-10","conditions":["Acute Ischemic Stroke"],"enrollment":2000,"completionDate":"2025-12-30"},{"nctId":"NCT01721798","phase":"NA","title":"Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women","status":"COMPLETED","sponsor":"FHI 360","startDate":"2013-11-10","conditions":["HIV"],"enrollment":199,"completionDate":"2018-07-13"},{"nctId":"NCT06212765","phase":"PHASE3","title":"Oral Citrulline Supplementation in COPD Patients With Malnutrition","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2024-01-25","conditions":["Chronic Obstructive Pulmonary Disease Severe","Malnutrition"],"enrollment":60,"completionDate":"2026-09-25"},{"nctId":"NCT05101265","phase":"PHASE1","title":"Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment","status":"UNKNOWN","sponsor":"PharmaMar","startDate":"2021-03-09","conditions":["Advanced Solid Tumor","Hepatic Impairment"],"enrollment":24,"completionDate":"2025-06-01"},{"nctId":"NCT04912115","phase":"PHASE2","title":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","status":"SUSPENDED","sponsor":"PharmaTher Inc.","startDate":"2021-10-05","conditions":["Dyskinesias","Movement Disorders","Central Nervous System Diseases","Nervous System Diseases","Neurologic Manifestations"],"enrollment":30,"completionDate":"2024-03-30"},{"nctId":"NCT06119802","phase":"","title":"Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation","status":"UNKNOWN","sponsor":"Yinglong Hou","startDate":"2022-01-01","conditions":["Atrial Fibrillation","Hyperuricemia"],"enrollment":10000,"completionDate":"2024-04-30"},{"nctId":"NCT06077539","phase":"PHASE1,PHASE2","title":"Dexmedetomidine Versus Ketamine Versus Magnesium Sulfate for the Prevention of Emergence Agitation Following Sevoflurane Induced Anesthesia in Cardiac Catheterization in Pediatrics","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-09-20","conditions":["Anesthesia Emergence Delirium"],"enrollment":100,"completionDate":"2024-05-01"},{"nctId":"NCT06042816","phase":"NA","title":"Analgesic Efficacy of Free-opioid Anesthesia for Colorectal Surgery","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2019-12-30","conditions":["Colorectal Cancer"],"enrollment":49,"completionDate":"2021-12-30"},{"nctId":"NCT01452503","phase":"NA","title":"Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6","status":"COMPLETED","sponsor":"FHI 360","startDate":"2007-05","conditions":["Contraception"],"enrollment":170,"completionDate":"2008-04"},{"nctId":"NCT05999331","phase":"","title":"Elevated Initial APRI Value Was Associated With SALD","status":"UNKNOWN","sponsor":"Chinese Medical Association","startDate":"2019-01-01","conditions":["Liver Dysfunction","Sepsis-associated Liver Dysfunction"],"enrollment":160,"completionDate":"2023-09-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Kabiven"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Perikabiven"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Clinisol"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Premasol - sulfite-free (Amino Acid)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn II"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn-PF"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ProSol"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Plenamine"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"TrophAmine"}]},"crossReferences":{"NUI":"N0000146991","MMSL":"NOCODE","NDDF":"000933","UNII":"30KYC7MIAI","VUID":"4018680","CHEBI":"CHEBI:22660","VANDF":"4018680","INN_ID":"1570","RXNORM":"1169","UMLSCUI":"C0004015","chemblId":"CHEMBL274323","ChEMBL_ID":"CHEMBL274323","KEGG_DRUG":"D00013","DRUGBANK_ID":"DB00128","PDB_CHEM_ID":" ASP","PUBCHEM_CID":"5960","SNOMEDCT_US":"44970006","IUPHAR_LIGAND_ID":"3309","MESH_DESCRIPTOR_UI":"D001224"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":18949,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 18","pmid":"41903465","title":"Metabolite-based genome-wide association analysis reveals genetic loci and candidate genes affecting breast muscle metabolites in Sansui ducks.","journal":"Poultry science"},{"date":"2026 Feb 27","pmid":"41901708","title":"Genotypic and Phenotypic Characterisation of Staphylococcus aureus Enterotoxins Using Single-Cell Raman Spectroscopy and Metabolomics.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 15","pmid":"41898315","title":"EEG Time-Frequency Clustering Reveals Spectral Signatures of Glutamatergic and Cholinergic Activities and Their Interrelations.","journal":"Biomedicines"},{"date":"2026 Feb 27","pmid":"41898192","title":"Serum Amino Acid and Fatty Acid Metabolites as Predictors of Sleep Disorders in Children: A Risk Prediction Model.","journal":"Biomedicines"},{"date":"2026 Mar 20","pmid":"41897948","title":"Impact of Dietary Lactobacillus plantarum on Muscle Composition, Hemolymph Biochemistry, Lipid Metabolism, and the mTOR Signaling Pathway in Red Claw Crayfish (Cherax quadricarinatus).","journal":"Animals : an open access journal from MDPI"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-08-17T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA019398"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-09-07T00:00:00.000Z","mah":"B BRAUN","brand_name_local":null,"application_number":"NDA019018"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-07-11T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA020015"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"ANDA020512"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-04-12T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA200656"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:39:05.703847+00:00","fieldsConflicting":16,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}